Gemcitabine plus nab-paclitaxel

Phase 2Small molecule

Gemcitabine plus nab-paclitaxel is one of 84 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

MS Contin

Merck & Co.

Preclinical

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Gemcitabine plus nab-paclitaxel

NNorthwell Health

Phase 2

1 5

ABI-007

Bristol-Myers Squibb

Preclinical

2 6

Thiazolidinediones

Sanofi

Preclinical

1 7

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 8

Meglitinides

Sanofi

Preclinical

1 9

Chemotherapy Agents

Takeda

Preclinical

1 10

Active Comparator

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT07163273

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·NNorthwell Health·Phase 2·NCT07163273·41 enrolled

Pancreatic Cancer1 trial

Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer

Completed·GGrupo Hospital de Madrid·N/A·NCT01442974·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Gemcitabine plus nab-paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gemcitabine plus nab-paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gemcitabine plus nab-paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwell Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNorthwell Health

Gemcitabine plus nab-paclitaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News